Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Conditions:   Neuroendocrine Tumors;   Carcinoid Syndrome Intervention:   Drug: Sandostatin Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain Terminated
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials